Research programme: psychedelics - BioNxt Solutions

Alternative Names: Psychedelic medicine programme - BioNxt Solutions

Latest Information Update: 07 Mar 2023

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator XPhyto Therapeutics
Developer BioNxt Solutions
Class Anti-infectives; Anti-inflammatories; Antidepressants; Antipsychotics; Anxiolytics; Behavioural disorder therapies; Dimethylamines; Drug withdrawal therapies; Indoles; Mood stabilisers; Neuropsychotherapeutics; Organophosphorus compounds; Phytotherapies; Small molecules
Mechanism of Action Cannabinoid receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

08 Jun 2021 Early research in Depressive disorders in Canada (unspecified route)
08 Jun 2021 Early research in Substance-related disorders in Canada (unspecified route)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com